The estimated Net Worth of David Edward Caligan Partne... is at least $15.5 Million dollars as of 28 May 2024. David Partne owns over 425,000 units of Liquidia Corp stock worth over $15,486,160 and over the last few years David sold LQDA stock worth over $0.
David has made over 3 trades of the Liquidia Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently David bought 425,000 units of LQDA stock worth $8,733,750 on 28 May 2024.
The largest trade David's ever made was buying 425,000 units of Liquidia Corp stock on 28 May 2024 worth over $8,733,750. On average, David trades about 105,058 units every 26 days since 2023. As of 28 May 2024 David still owns at least 1,525,730 units of Liquidia Corp stock.
You can see the complete history of David Partne stock trades at the bottom of the page.
David's mailing address filed with the SEC is 515 MADISON AVENUE515 MADISON AVENUE, 8TH FLOOR8TH FLOOR, NEW YORKNEW YORK, NYNY, 1002210022.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell und Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: